BloodPAC published generic analytical validation protocols for tumor‑informed circulating tumor DNA (ctDNA) MRD assays to harmonize limit‑of‑detection, accuracy, precision and robustness testing across platforms. The guidance, developed with experts from industry, pharma, academia and regulators, aims to speed adoption of validated MRD assays and support clinical and regulatory comparability. Simultaneously, commercial labs announced expanded MRD offerings: Labcorp launched Plasma Detect ID and Plasma Detect Genome assays and Saga Diagnostics expanded Pathlight MRD into colorectal cancer. Companies stressed low limits of detection and clinical studies supporting the tests’ use for surveillance and recurrence risk stratification.